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Abstract 
 
Acetaminophen, an effective and popular over-the-counter pain reliever (e.g., Tylenol®), has 
recently been shown to blunt individuals’ reactivity to a range of negative stimuli beyond 
physical pain. Because past psychological and neuroimaging research has linked reduced 
sensitivity to negative reactions to similarly diminished sensitivity to positive reactions, we 
conducted two experiments testing whether acetaminophen might blunt individuals’ evaluations 
and emotional experiences to both negative and positive stimuli alike. In each study, participants 
received either acetaminophen or placebo, and evaluated emotionally evocative stimuli on 
valence (Study 1 and 2), emotional arousal (Study 1 and 2), and non-evaluative aspects (Study 
2). Results revealed that participants taking acetaminophen (versus placebo) evaluated 
unpleasant stimuli less negatively and pleasant stimuli less positively, and were less emotionally 
aroused overall. Conversely, non-evaluative judgments were unaffected by treatment. These 
findings suggest that the mechanism by which acetaminophen reduces pain may more broadly 
blunt individuals’ evaluative and emotional processing. 
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When people experience aches and pains, one of the most common treatments they reach 
for is acetaminophen (the active ingredient in Tylenol®). Pain is a fundamentally negative, 
emotionally taxing experience that motivates individuals to relieve it as soon as possible 
(Seymour & Dolan, 2013; see Wall & Melzack, 2013), and acetaminophen is the most popular 
over-the-counter means of pain relief in the United States, being taken by an estimated 50 
million Americans each week (Kaufman et al., 2002; McNeil Consumer HealthCare, 2002). Its 
popularity as a pain reliever makes sense, given its relatively fast onset (11-60 minutes) and 
lasting effect (1-4 hours; Anderson, 2008; McQuay et al., 2007; Pini, Sandrini, & Vitale, 1996; 
Smith, 2009).  
However, recent evidence suggests that acetaminophen might be capable of soothing 
more than our bodily aches and pains. Indeed, these studies have provocatively demonstrated 
that acetaminophen reduces individuals’ sensitivity to a range of non-physical negative 
experiences. When taken over the course of three weeks, for instance, acetaminophen (versus 
placebo) reduces individuals’ reported negative reactions resulting from feeling rejected in social 
relationships (DeWall et al., 2010). This finding is consistent with prior notions that pains 
originating from both physical and social sources share common neurochemical underpinnings 
(Panksepp, 1998).  
A one-time dose yields similar attenuating effects on individuals’ negative reactions 
toward less figuratively ”painful” experiences. Specifically, Randles, Heine, and Santos (2013) 
found that participants receiving an acute dose of 1000mg of acetaminophen (versus placebo) 
exhibited reduced negative reactions to thinking about their own mortality or toward nonsensical 
absurdist art. More recent findings further demonstrated that acetaminophen can similarly reduce 
negative reactions arising from difficult decisions (DeWall, Chester, & White, 2014). 
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Acetaminophen: Psychological Mechanisms of Action 
This collection of observations raises a pertinent question: How can a pain reliever have a 
common ameliorating effect on such a wide range of negative experiences, “painful” or 
otherwise? One potential explanation is that acetaminophen affects the magnitude of individuals’ 
reactivity to any psychologically unpleasing stimulus. Though the specific bodily sites where 
acetaminophen exerts its effects are still not properly understood (Anderson, 2008; Pini et al., 
1996; Smith, 2009), accumulating evidence indicates that they reside within the brain (Graham, 
Davies, Day, Mohamudally, & Scott, 2013). Thus, acetaminophen potentially validates the 
mantra that “pain is a state of mind.”  
Consistent with this notion, acetaminophen has been found to reduce neural activity in 
the anterior insula and anterior cingulate during an experience of social rejection (DeWall et al., 
2010). The anterior insula and cingulate form key nodes in the pain matrix and appear to be 
primarily responsible for the affective componant of pain (Eisenberger, 2012; Rainville, Duncan, 
Price, Carrier, & Bushnell, 1997; Schreckenberger et al., 2005; see Apkarian et al., 2013). For 
example, people with lesions in the affective pain matrix report that they continue to experience 
the pain, but that it no longer bothers them (Berthier, Starkstein, & Leiguarda, 1988; Corkin & 
Hebben, 1981; Foltz & White, 1962; Hurt & Ballantine, 1973). Moreover, lesions to the affective 
pain matrix seem to affect individuals’ evaluations toward both negative and positive stimuli 
more generally (Berntson, Norman, Bechara, Bruss, Tranel, and Cacioppo, 2011).  
In short, acetaminophen appears to exert its effects by altering brain activity, particularly 
within the affective pain matrix. As a result, and as demonstrated by recent evidence (DeWall et 
al., 2010; DeWall et al., 2014; Randles et al., 2013), acetaminophen seems capable of blunting 
the extent to which people experience a range of negative psychological reactions, be they 
physically painful, socially hurtful, judgmentally difficult, or generally unsettling. Furthermore, 
the attenuating effect of acetaminophen on insular and cingulate activity in response to a 
negative stimulus appears to be related to decreases in self-reported negative reactions to these 
unpleasant experiences. This connection between blunted psychological activity and diminished 
negative sensitivity invites the consideration of an intriguing possibility: Is acetaminophen more 
broadly blunting how individuals experience any emotional experience?  
 
Acetaminophen Blunts Negative and Positive Reactions Alike? 
Indeed, if acetaminophen is altering individuals’ negative sensitivity to unpleasant 
experiences, a wealth of theories and evidence from psychological and neuroimaging research 
suggest that it may also be capable of altering their positive sensitivity to pleasant experiences 
by altering common psychological evaluative processes. Individual differences in “affect 
intensity,” for example, predict the extremity to which people evaluate both negative and 
positive emotional experiences (Diener, Larsen, Levine, & Emmons, 1985; Larsen & Diener, 
1987; Larsen, Diener, & Emmons, 1986; Schimmack & Diener, 1997), and people who report 
fewer negative life events also report having fewer positive events (Suh, Diener, & Fujita, 1996). 
Likewise, people who experience fewer and less extreme negative moods also report 
experiencing fewer and less extreme positive moods (Crawford & Henry, 2004; see also Russell 
& Carroll, 1999). 
Related research from developmental psychology, especially differential susceptibility 
theory (Belsky & Pluess, 2009), suggests that people who are more or less sensitive to negative 
experiences are similarly more or less sensitive to positive experiences in like fashion. More 
specifically, in contrast with diathesis-stress models of childhood development (Monroe & 
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Simons, 1991), differential susceptibility theory predicts that children who are more vulnerable 
to failure (i.e., temperamental) within negative stressful environments might also be more likely 
to thrive in especially positive and nurturing environments during childhood. It follows, then, 
that children who are less affected by negative childhood experiences would be less responsive 
to positive childhood environments. 
Finally, neuroimaging research has shown that negative and positive stimuli alike lead to 
activation of cognitive networks that are related to broader evaluative and emotional processes, 
including the aforementioned affective pain matrix (Britton et al., 2006; Craig, 2009; Hamann, 
Ely, Hoffman, & Kilts, 2002; Gu, Hof, Friston, & Fan, 2013; Jabbi, Swart, & Keysers, 2007; 
Knutson & Greer, 2008; Lindquist & Barrett, 2012; Pollatos, Gramann, & Schandry, 2007). An 
especially illustrative example of both positive and negative evaluative processes relying on a 
common neural area was a lesion study conducted by Berntson and colleagues (2011), wherein 
the authors examined how individuals with damage to the insula (versus amygdala and control 
regions) evaluated negative and positive images from the International Affective Picture System 
(IAPS; Lang, Bradley, & Cuthbert, 2008). Their results indicated that insular damage (versus 
amygdala and control regions) led people to evaluate unpleasant stimuli less negatively and 
pleasant stimuli less positively. As a consequence, these attenuated evaluations led participants 
with insular lesions to feel less emotionally aroused from negative and positive stimuli alike. 
This last result is especially intriguing, given that the insula seems to be a critical 
mechanism through which acetaminophen reduces individuals’ emotional reactions toward 
negative stimuli (e.g., DeWall et al., 2010). But, as the extant research from a variety of areas 
reviewed here delineates, factors which influence individuals’ sensitivity to negative reactions 
can also diminish their sensitivity to positive experiences via common psychological evaluative 
processes. Taken together, these observations suggest that, if acetaminophen blunts negative 
reactions by attenuating the activation of broader evaluative psychological processes through the 
insula, acetaminophen may be more globally blunting reactions toward any negative or positive 
stimulus.  
Thus, although the existing research has focused on how acetaminophen attenuates 
individuals’ reactivity to a variety of negative stimuli, we propose that this drug may more 
generally affect individuals’ evaluations, particularly toward emotionally evocative stimuli. That 
is, contrary to existing assumptions, acetaminophen may actually reduce positive emotional 
reactions as well as negative ones. We therefore predicted that people taking acetaminophen 
(versus placebo) would experience blunted negative reactions to unpleasant stimuli and blunted 
positive reactions to pleasant stimuli. Our first experiment was designed as an initial test of this 
prediction. [1249w] 
 
Study 1 
Method. Eighty-three participants were recruited to participate in an experiment on 
“Tylenol® and social cognition” in exchange for course credit. Participants were randomly 
assigned to take an acute dose of 1000mg of acetaminophen or placebo in liquid vehicle. 
Experimenters and participants were unaware of participants' assignment to condition. 
After a 60-minute waiting period to allow acetaminophen to enter the brain (Anderson, 
2008; H.S. Smith, 2009), participants completed all relevant measures on computers within 
individual cubicles to evaluate 40 randomly presented pictures from the International Affective 
Picture System (IAPS; Lang, Bradley, & Cuthbert, 2008) on two dimensions. First, participants 
evaluated each stimulus in a random order by responding to the question, “To what extent is this 
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picture positive or negative?”, using an 11-point scale anchored at -5 (“extremely negative”) and 
+5 (“extremely positive”). Then, participants saw all 40 images in a newly random order and 
provided ratings of their emotional arousal by responding to the question, “To what extent does 
this picture make you feel an emotional reaction?” using an 11-point scale where 0 = “I feel little 
to no emotion,” and 10 = “I feel an extreme amount of emotion” (Berntson et al., 2011), among 
other unrelated measures. For both measures, each stimulus was present on-screen until 
participants indicated their responses.  
IAPS stimuli were selected to sample from a variety of emotional experiences and social 
versus nonsocial contexts, and were grouped a priori into five categories based on normative 
evaluations (Berntson et al., 2011; Lang et al., 2008). More specifically, corresponding normative 
ratings on valence were used to select 10 extremely unpleasant stimuli (IAPS ID: 2205, 2683, 
2730, 2800, 3301, 3530, 6350, 9040, 9300, 9571), 5 moderately unpleasant stimuli (1270, 2590, 
2694, 5971, 9001), 10 neutral stimuli (1670, 2372, 2570, 5395, 5520, 7000, 7041, 7175, 7186, 
7224), 5 moderately pleasant stimuli (1450, 1602, 2510, 2791, 5711), and 10 extremely pleasant 
stimuli (2040, 2091, 4626, 4660, 5470, 7502, 8185, 8190, 8200, 8501).  
From participants’ responses, we computed three measures each for their evaluations and 
emotional arousal. First, participants’ overall evaluation extremity (distance from the scale 
midpoint; Abelson, 1995) and overall emotional arousal toward all 40 stimuli were computed as 
global average scores of their evaluation extremity and emotional arousal, respectively. Then, 
participants’ evaluation extremity and emotional arousal toward neutral, moderate (both positive 
and negative), and extreme (both positive and negative) stimuli were computed in order to 
analyze how stimulus extremity, regardless of its negative or positive normative rating, might be 
affected as a function of treatment. Finally, participants’ raw evaluations and emotional arousal 
toward the stimuli were averaged within each of the five normative stimulus categories 
(extremely unpleasant, moderately unpleasant, neutral, moderately pleasant, extremely pleasant) 
to analyze how these measures might be affected by treatment in varying directions.  
Results. Six participants who exhibited abnormal response patterns on evaluations or 
emotional arousal (e.g., rating neutral stimuli more negatively than moderately or extremely 
unpleasant stimuli) were excluded, leaving N=77 for final analyses. At the end of the study, 
participants responded whether they thought they took acetaminophen, placebo, or if they had no 
idea. 45% of participants indicated that they did not know. Among participants who guessed, a 
chi-square test of independence was performed to examine whether actual treatment predicted 
participants’ perceived treatment. As expected, this relation was not significant, χ2(1,N=46) = 
2.36, p = .124, such that 47% of participants guessing that they took acetaminophen were 
actually in the placebo condition. 
Evaluations 
We first submitted participants’ global evaluation extremity toward all stimuli to an 
independent-samples t-test, with treatment as the between-participants factor. This analysis 
yielded a significant difference between treatments, t(75) = 2.79, p = . 007, ηp2 = .094. Overall, 
participants taking acetaminophen were significantly less extreme in their evaluations (M = 1.93) 
compared to participants receiving placebo (M = 2.27).  
Next, we submitted participants’ evaluation extremity to the stimuli as categorized by 
their neutral, moderate, or extreme normative rating to a 2 [Treatment: acetaminophen, placebo] 
x 3 [Normative Rating: neutral, moderate, or extreme] mixed-model ANOVA, with treatment as 
between-participants and normative rating as within-participants factors. Mauchly’s test 
indicated that the assumption of sphericity had been violated, χ2(2) = 7.63, p = .022, so degrees 
Running Head: Acetaminophen and Evaluation 6 
of freedom were corrected using Greenhouse-Geisser estimates of sphericity (ε=0.91). A main 
effect of category was found, F(1.8, 133.0) = 588.72, p < .001, ηp2 = .887, such that participants 
rated neutral stimuli least extremely (in either a positive or negative direction), moderate stimuli 
relatively more extremely than neutral stimuli, and extreme stimuli relatively more extremely 
than moderate stimuli, reflecting normative ratings. 
Critically, however, this analysis yielded a main effect of treatment, F(1,75) = 6.74, p = 
.011, ηp2 = .082, and the predicted interaction of treatment by category, F(1.8, 133.0) = 4.68, p = 
.013, ηp2 = .059. As with the overall extremity score analyses, participants taking acetaminophen 
were overall less extreme in their evaluations across categories (M = 1.59) compared to 
participants receiving placebo (M = 1.87). Contrast analyses within each category of stimuli 
revealed that participants taking acetaminophen evaluated both extreme stimuli (M = 2.94) and 
moderate stimuli (M = 1.48) less extremely (in either a positive or negative direction) than did 
participants receiving placebo (Ms = 3.48, 1.79, ps = .006, .041, respectively). Evaluation 
extremity toward neutral stimuli did not differ as a function of treatment, p = .846.  
Lastly, we performed a 2 [Treatment: acetaminophen, placebo] x 5 [Normative Rating: 
extremely unpleasant, moderately unpleasant, neutral, moderately pleasant, extremely pleasant] 
mixed-model ANOVA on participants’ raw evaluations, averaged within each category of stimuli. 
Mauchly’s test indicated that the assumption of sphericity had been violated, χ2(9) = 86.12, p < 
.001, so degrees of freedom were corrected using Huynh-Feldt estimates of sphericity (ε=0.62). 
A main effect of category was found, F(2.4, 176.8) = 561.09, p < .001, ηp2 = .882, such that 
participants rated extremely unpleasant pictures more negatively and extremely pleasant pictures 
more positively in a linear fashion, reflecting normative ratings. There was no main effect of 
treatment on evaluations, F(1,75) = 0.43, p = .514, ηp2 = .006, indicating that treatment did not 
significantly change overall evaluations in any one direction. 
Critically, however, the predicted interaction of treatment by category was obtained, 
F(2.4, 176.8) = 5.11, p = .004, ηp2 = .064. Contrast analyses revealed that participants taking 
acetaminophen rated extremely unpleasant (M = -3.25) significantly less negatively than did 
participants taking placebo (M = -3.74, p = .023). And, participants taking acetaminophen rated 
extremely pleasant stimuli (M = +2.58) significantly less positively than did participants 
receiving placebo (M = +3.21, p = .010). Participants taking acetaminophen also tended to rate 
moderately unpleasant stimuli less negatively (M = -1.49) than participants taking placebo (Ms = 
-1.78, p = .203), and also tended to rate moderately pleasant stimuli less positively (M = +1.23) 
than participants receiving placebo (M = +1.69, p = .065), although these differences were 
marginally significant or trending. Neutral stimuli evaluations did not differ by treatment, p = 
.850.  
Emotional Arousal 
Next, we submitted participants’ emotional arousal ratings to similar analyses as done 
with evaluations. We first submitted participants’ overall emotional arousal toward all stimuli to 
an independent-samples t-test, with treatment as the between-participants factor. This analysis 
yielded a marginally significant difference between treatments, t(75) = 1.62, p = .109, ηp2 = .034. 
Overall, participants taking acetaminophen tended to be less emotionally aroused by the stimuli 
(M = 5.34) compared to participants receiving placebo (M = 5.77).  
Then, we submitted participants’ emotional arousal to the stimuli as categorized by their 
neutral, moderate, or extreme normative ratings to a 2 [Treatment: acetaminophen, placebo] x 3 
[Normative Rating: neutral, moderate, or extreme] mixed-model ANOVA, with treatment as 
between-participants and normative rating as within-participants factors. Mauchly’s test 
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indicated that the assumption of sphericity had been violated, χ2(2) = 23.32, p < .001, so degrees 
of freedom were corrected using Greenhouse-Geisser estimates of sphericity (ε=0.79). A main 
effect of category was found, F(1.6, 118.1) = 379.72, p < .001, ηp2 = .835, such that participants 
were least emotionally aroused by neutral stimuli, were relatively more emotionally aroused by 
moderately pleasant and unpleasant stimuli, and were most emotionally aroused by extremely 
pleasant and unpleasant stimuli, reflecting normative ratings. This analysis did not yield a 
significant main effect of treatment, F(1,75) = 1.86, p = .177, ηp2 = .024, although it was in the 
expected direction. Specifically, participants taking acetaminophen tended to report lower 
emotional arousal overall to the stimuli (M = 4.84) compared to participants receiving placebo 
(M = 5.20). 
Critically, however, these effects were qualified by the predicted interaction of treatment 
by category, F(1.6, 118.1) = 3.85, p = .033, ηp2 = .049. Contrast analyses within each category of 
stimuli revealed that participants taking acetaminophen were significantly less emotionally 
aroused by extreme stimuli (M = 6.86) than were participants receiving placebo (M = 7.48, p = 
.045). Likewise, participants taking acetaminophen tended to express diminished emotional 
arousal toward moderate stimuli (M = 4.85) relative to participants receiving placebo (M = 5.46, 
p = .084), although this difference was marginally significant. Emotional arousal toward neutral 
stimuli did not differ as a function of treatment, p = .616. 
Finally, we submitted participants’ emotional arousal ratings within each of the five 
normative categories to the same 2x5 mixed-model ANOVA as with their evaluations. Mauchly’s 
test indicated that the assumption of sphericity had been violated, χ2(9) = 41.21, p < .001, so 
degrees of freedom were corrected using Greenhouse-Geisser estimates of sphericity (ε=0.76). A 
main effect of picture category was obtained, F(3.0, 229.0) = 216.26, p < .001, ηp2 = .742, such 
that participants expressed higher emotional arousal toward stimuli that were normatively more 
extreme in valence in a quadratic fashion, with the highest arousal toward extremely unpleasant 
and extremely pleasant stimuli, and the lowest arousal toward neutral stimuli. 
Critically, however, a marginally significant main effect of treatment was obtained, 
F(1,75) = 2.83, p = .097, ηp2 = .036, as was a tendency for the predicted interaction, F(3.0, 229.0) 
= 1.72, p = .164, ηp2 = .022, although it was not statistically significant. As observed in previous 
analyses, participants taking acetaminophen tended to report lower levels of arousal toward all 
stimuli (M = 5.24) than did participants taking placebo (M = 5.71). Contrast analyses indicated 
that participants taking acetaminophen were significantly less emotionally aroused by extremely 
pleasant stimuli (M = 6.00) than were participants taking placebo (M = 6.74, p = .047). Similarly, 
participants receiving acetaminophen were marginally significantly less emotionally aroused by 
moderately unpleasant stimuli (M = 5.67) than were participants assigned the placebo condition 
(M = 6.33, p = .090). Furthermore, participants taking acetaminophen tended to be less 
emotionally aroused by moderately pleasant stimuli (M = 4.03) and less emotionally aroused by 
extremely unpleasant stimuli (M = 7.72) than were participants taking placebo (Ms = 4.59, 8.23, 
ps = .173, .166, respectively), although these differences were not statistically significant. 
Emotional arousal toward neutral stimuli did not differ significantly as a function of treatment, p 
= .616. In all, acetaminophen (versus placebo) attenuated participants’ emotional reactivity more 
potently toward stimuli that were increasingly extreme in valence, regardless of direction. 
 
Discussion 
These findings replicate and expand on past results showing that acetaminophen can 
effectively attenuate individuals’ experienced negativity toward unpleasant stimuli (DeWall et 
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al., 2010; DeWall et al., 2014; McQuay et al., 2007; Randles et al., 2013), even when these 
affective experiences are merely in response to viewing relatively impersonal photographic 
stimuli. However, Study 1 demonstrated for the first time that acetaminophen similarly 
attenuates individuals’ experienced positivity toward increasingly pleasant stimuli. It also was 
found that acetaminophen (versus placebo) broadly diminished the emotional arousal that people 
experienced toward the increasingly extreme stimuli, regardless of direction, although these 
results were statistically weaker compared to evaluations. These results provide initial support 
for the notion that that acetaminophen appears to reduce perceived pain because its mechanism 
of action works more broadly to blunt individuals’ valence sensitivity to negative and positive 
experiences alike, rather than acting specifically on painful experiences per se. 
What remains unclear, however, is whether these effects are truly effects of 
acetaminophen on evaluative judgments, or whether acetaminophen affects any judgment of 
relative magnitude (e.g., saturation, size). Furthermore, though the results on emotional arousal 
were promising, they were statistically weaker than those obtained for the effect acetaminophen 
on evaluations. In all, the specific consequences of acetaminophen on evaluation extremity, 
compared to other psychologically relevant outcomes, remain speculative based on Study 1.  
Thus, we designed a second experiment to address these issues. First, we thought it was 
critical to replicate the novel finding that acetaminophen blunts evaluation extremity toward 
negative and positive stimuli alike. Additionally, we wanted to test for more convincing evidence 
that acetaminophen attenuates not just evaluation extremity, but emotional arousal as well. 
Finally, we sought to test whether the effects of acetaminophen on diminished evaluation 
extremity are due to a more global attenuation of any judgments of magnitude, or whether its 
effect is specific to evaluations of relative negativity and positivity. Thus, Study 2 aimed to 
replicate and bolster the findings of Study 1, with the additional goal of examining whether 
acetaminophen blunts any and all judgments of magnitude, or if its effects are specific to 
evaluations. [347w] 
 
Study 2 
Method. Ninety-one participants were recruited to participate in an experiment on 
“Tylenol® and social cognition” in exchange for course credit. Participants were randomly 
assigned to take an acute dose of 1000mg of acetaminophen or placebo, in liquid vehicle. 
Experimenters and participants were unaware of participants’ assignment to condition. 
The procedure and stimuli were identical to Study 1, with participants providing one 
additional rating of each stimulus. After indicating their evaluations of and emotional  arousal 
toward each stimulus, participants saw all images one last time, in a newly randomized order, 
and indicated the extent to which each picture contained the color blue, responding for each 
picture to the question, “To what extent is the color blue represented in this picture?” using an 
11-point scale, where 0 = “The picture has zero blue color,” and 10 = “This picture is 100% the 
color blue.” This measure was designed to have participants focus on a dimension of judgment 
about each picture that would be minimally influenced by evaluative aspects of each picture, in 
order to test whether acetaminophen affects evaluations specifically, or if it blunts any and all 
judgments of magnitude. 
Results. 10 participants who exhibited abnormal response patterns on evaluations or 
emotional arousal (e.g., rating extremely unpleasant stimuli less negatively than moderately 
unpleasant stimuli) were excluded, leaving N=81 for final analyses. At the end of the study, 
participants indicated whether they thought they took acetaminophen or placebo. A chi-square 
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test of independence was performed to examine whether actual treatment predicted participants’ 
perceived treatment. As expected, this relation was not significant, χ2(1,N=81) = 0.08, p = .774, 
such that 51% of participants guessing that they took acetaminophen were actually in the placebo 
condition. 
Evaluations 
As in Study 1, we computed the extent to which participants’ ratings of each stimulus was 
distant from the scale midpoint (extremity scores), arriving at two measures: An overall measure 
of participants’ evaluation extremity toward all 40 stimuli, as well as participants’ evaluation 
extremity within each of the neutral, moderate (both pleasant and unpleasant), and extreme (both 
pleasant and unpleasant) categories of stimuli. 
We first submitted participants’ overall evaluation extremity to all stimuli to an 
independent-samples t-test, with treatment as the between-participants factor. This analysis 
yielded a significant result, t(79) = 2.05, p = . 043, ηp2 = .051, such that participants’ taking 
acetaminophen were overall less extreme in their evaluations (M = 1.59) compared to 
participants receiving placebo (M = 1.80). 
Next, we submitted participants’ evaluation extremity to the stimuli as categorized by 
their neutral, moderate, or extreme normative rating to a 2 [Treatment: acetaminophen, placebo] 
x 3 [Normative Rating: neutral, moderate, or extreme] mixed-model ANOVA, with treatment as 
between-participants and normative rating as within-participants factors. Mauchly’s test 
indicated that the assumption of sphericity had been violated, χ2(2) = 17.74, p < .001, so degrees 
of freedom were corrected using Greenhouse-Geisser estimates of sphericity (ε=0.83). A main 
effect of category was found, F(1.7, 131.3) = 539.23, p < .001, ηp2 = .872, such that participants 
rated neutral stimuli least extremely (in either a positive or negative direction), moderate stimuli 
relatively more extremely than neutral stimuli, and extreme stimuli relatively more extremely 
than moderate stimuli, reflecting normative ratings. 
Critically, however, this analysis yielded the predicted main effect of treatment, F(1,79) = 
3.48, p = .066, ηp2 = .042, and the predicted interaction of treatment by category, F(1.7, 131.3) = 
3.02, p = .062, ηp2 = .037, although both effects in this study were instead marginally significant. 
As with the overall extremity score analyses, participants taking acetaminophen were overall less 
extreme in their evaluations across categories (M = 1.64) compared to participants receiving 
placebo (M = 1.84). Contrast analyses within each category of stimuli revealed that participants 
taking acetaminophen evaluated extreme stimuli (M = 3.02) significantly less extremely (in 
either a positive or negative direction) than did participants receiving placebo (Ms = 3.47, p = 
.029). Likewise, participants taking acetaminophen tended to express diminished evaluation 
extremity toward moderate stimuli (M = 1.61) relative to participants receiving placebo (M = 
1.77, p = .294), although in this study this difference was not statistically different. Evaluation 
extremity toward neutral stimuli did not differ as a function of treatment, p = .946.  
Finally, we performed a 2 [Treatment: acetaminophen, placebo] x 5 [Normative Rating: 
extremely unpleasant, moderately unpleasant, neutral, moderately pleasant, extremely pleasant] 
mixed-model ANOVA on participants’ evaluations of IAPS stimuli from each category. 
Mauchly’s test indicated that the assumption of sphericity had been violated, χ2(9) = 148.16, p < 
.001, so degrees of freedom were corrected using Huynh-Feldt estimates of sphericity (ε=0.49). 
A main effect of category was found, F(2.0, 155.1) = 632.60, p < .001, ηp2 = .883, such that 
participants rated extremely unpleasant pictures more negatively and extremely pleasant pictures 
more positively, with other categories falling in a typical linear fashion, reflecting normative 
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ratings. There was no main effect of treatment on evaluations, F(1,79) = 1.26, p = .265, 
indicating that treatment did not significantly change overall evaluations in any one direction. 
Once again, as in Study 1, these effects were qualified by the predicted interaction of 
treatment by category, F(2.0, 155.1) = 2.89, p = .062, ηp2 = .035, although in this study the effect 
of the interaction was marginally significant. Contrast analyses revealed that participants taking 
acetaminophen rated extremely pleasant (M = +2.60) significantly less positively than did 
participants receiving placebo (M = +3.18, p = .014). Likewise, participants taking 
acetaminophen tended to rate extremely unpleasant stimuli less negatively (M = -3.44) than did 
participants receiving placebo (M = 3.75, p = .139), although this difference was not statistically 
significant in this study. And, participants taking acetaminophen tended to rate moderately 
unpleasant stimuli less negatively (M = -1.85) and moderately pleasant stimuli less positively (M 
= +1.27) compared to participants receiving placebo (Ms = -2.01, +1.42), although these 
differences were not statistically significant (ps = .458, .498, respectively). Finally, participants 
taking acetaminophen unexpectedly evaluated neutral stimuli significantly less positively (M = -
0.03) than did participants receiving placebo (M = +0.19, p = .018).  
Emotional Arousal 
Next, we submitted participants’ emotional arousal ratings to similar analyses as 
evaluations, as in Study 1. Specifically, we first averaged participants’ emotional arousal ratings 
to all 40 stimuli to derive a score of participants’ overall emotional arousal. Next, we averaged 
emotional arousal ratings within each of the neutral, moderate, and extreme categories of stimuli 
(collapsing across positive and negative valence, as done with evaluations). Finally, we then 
submitted participants’ average emotional arousal ratings within each of the five categories of 
stimuli, as with evaluations. 
We first submitted participants’ overall emotional arousal to all stimuli to an independent-
samples t-test, with treatment as the between-participants factor. This analysis yielded a 
significant result, t(79) = 2.60, p = . 011, ηp2 = .079. Participants taking acetaminophen were 
overall less emotionally aroused by the stimuli (M = 4.18) compared to participants receiving 
placebo (M = 4.82). 
Next, we submitted participants’ emotional arousal to the stimuli as categorized by their 
neutral, moderate, or extreme normative ratings to a 2 [Treatment: acetaminophen, placebo] x 3 
[Normative Rating: neutral, moderate, or extreme] mixed-model ANOVA, with treatment as 
between-participants and normative rating as within-participants factors. Mauchly’s test 
indicated that the assumption of sphericity had been violated, χ2(2) = 43.06, p < .001, so degrees 
of freedom were corrected using Hunyh-Feldt estimates of sphericity (ε=0.72). A main effect of 
category was found, F(1.4, 113.8) = 438.09, p < .001, ηp2 = .847, such that participants were least 
emotionally aroused by neutral stimuli, were relatively more emotionally aroused by moderate 
pleasant and unpleasant stimuli, and were most emotionally aroused by extreme pleasant and 
unpleasant stimuli, reflecting normative ratings. 
Critically, however, this analysis yielded a significant main effect of treatment, F(1,79) = 
5.78, p = .019, ηp2 = .068, and the predicted interaction of treatment by category, F(1.4, 113.8) = 
2.52, p = .101, ηp2 = .031, although the effect of the interaction was only marginally significant. 
As seen in the prior analyses, participants taking acetaminophen were overall less emotionally 
aroused across categories (M = 4.66) compared to participants receiving placebo (M = 5.35). 
Contrast analyses within each category of stimuli revealed that participants taking 
acetaminophen were significantly less emotionally aroused by extreme stimuli (M = 6.91) than 
were participants receiving placebo (M = 8.05, p = .007). Likewise, participants taking 
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acetaminophen tended to express less emotional arousal toward moderate stimuli (M = 5.01) 
relative to participants receiving placebo (M = 5.49, p = .189), although this difference was not 
statistically significant. Lastly, somewhat unexpectedly, participants taking acetaminophen also 
tended to be less emotionally aroused by neutral stimuli (M = 2.06) compared to participants 
receiving placebo (M = 2.50, p = .104).  
We then submitted participants’ emotional arousal ratings within each of the five 
normative categories to the same 2x5 mixed-model ANOVA as with their evaluations. Mauchly’s 
test indicated that the assumption of sphericity had been violated, χ2(9) = 70.69, p < .001, so 
degrees of freedom were corrected using Huynh-Feldt estimates of sphericity (ε=0.70). A main 
effect of picture category was obtained, F(2.8, 220.6) = 245.91, p < .001, ηp2 = .757, such that 
participants expressed higher emotional arousal toward stimuli that were normatively more 
extreme in valence in a quadratic fashion, with the highest arousal toward extremely unpleasant 
and extremely pleasant stimuli, and the lowest arousal toward neutral stimuli. 
Critically, however, a main effect of treatment was obtained, F(1,79) = 5.47, p = .022, ηp2 
= .065, as was a tendency for the predicted interaction, F(2.8, 220.6) = 1.95, p = .127, ηp2 = .024, 
although it was not statistically significant. As observed in previous analyses, participants taking 
acetaminophen reported lower levels of arousal toward all stimuli (M = 5.18) than did 
participants taking placebo (M = 5.92). Contrast analyses indicated that participants taking 
acetaminophen were significantly less emotionally aroused by extremely pleasant stimuli (M = 
5.97) than were participants taking placebo (M = 7.38, p = .001). Similarly, participants receiving 
acetaminophen were marginally significantly less emotionally aroused by extremely unpleasant 
stimuli (M = 7.84) than were participants assigned the placebo condition (M = 8.72, p = .077). 
Furthermore, participants taking acetaminophen tended to be less emotionally aroused by 
moderately pleasant stimuli (M = 3.91) and less emotionally aroused by moderately unpleasant 
stimuli (M = 6.11) than were participants taking placebo (Ms = 4.33, 6.65, ps = .303, .238, 
respectively), although these differences were not statistically significant. Finally, participants 
taking acetaminophen unexpectedly tended to be less emotionally aroused toward neutral stimuli 
(M = 2.06) than were participants taking placebo (M = 2.50), p = .104. In all, acetaminophen 
(versus placebo) attenuated participants’ emotional reactivity more potently toward stimuli that 
were increasingly extreme in valence, regardless of direction.  
Non-evaluative Judgments (Blue Content Ratings) 
Finally, participants’ ratings of how much of the color blue was represented in all of the 
stimuli, as well as their ratings within each of five quintiles (based on RGB-computed blue 
content analyses). We first submitted participants’ overall blue ratings to all stimuli to an 
independent-samples t-test, with treatment as the between-participants factor. This analysis 
yielded a non-significant result, t(79) = -0.25, p = .802, ηp2 = .001, such that participants’ taking 
acetaminophen did not differ in their blueness ratings of stimuli overall (M = 3.42) compared to 
participants receiving placebo (M = 3.38). 
We then submitted participants’ blue ratings across the five quintiles of IAPS stimuli to a 
2 [Treatment: acetaminophen, placebo] x 5 [Objective Rating: bottom quintile, second quintile, 
third quintile, fourth quintile, top quintile] mixed-model ANOVA. Mauchly’s test indicated that 
the assumption of sphericity had been violated, χ2(9) = 41.46, p < .001, so degrees of freedom 
were corrected using Greenhouse-Geisser estimates of sphericity (ε=0.78). Objective category 
was a significant predictor of participants’ blue ratings, F(3.1, 247.9) = 258.56, p < .001, ηp2 = 
.766, indicating that participants rated these stimuli as being meaningfully different in the extent 
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to which the color blue was represented across quintiles, reflecting RGB-computed blue content 
ratings.  
However, there was no effect of treatment, F(1,79) = 0.06, p = .802, ηp2 = .001, and no 
interaction of treatment by category, F(3.1, 247.9) = 0.21, p = .899, ηp2 = .003. Contrast analyses 
corroborated these findings, revealing that treatment did not significantly affect color saturation 
judgments within any individual quintile, ps > .6. Thus, these results suggest that the blunting 
effects of acetaminophen (versus placebo) appear to be unique to evaluative (versus non-
evaluative) processes. 
Combined study analyses. In accord with recommended approaches to meta-analyzing 
multiple studies (Eich, 2014), we combined the two studies (N=158) and submitted participants’ 
evaluations and emotional arousal to the same three analyses that were conducted within each 
study. 
Evaluations 
On evaluations, participants’ overall evaluation extremity to all stimuli was submitted to 
an independent-samples t-test, with treatment as the between-participants factor. This analysis 
yielded a significant result, t(156) = 3.26, p = . 001, ηp2 = .064 (Figure 1). Specifically, 
participants taking acetaminophen were overall less extreme in their evaluations (M = 1.75) 
compared to participants receiving placebo (M = 2.03).  
Next, we submitted participants’ evaluation extremity to the stimuli as categorized by 
their neutral, moderate, or extreme normative categories to a 2 [Treatment: acetaminophen, 
placebo] x 3 [Normative Rating: neutral, moderate, or extreme] mixed-model ANOVA, with 
treatment as between-participants and normative rating as within-participants factors. Mauchly’s 
test indicated that the assumption of sphericity had been violated, χ2(2) = 22.69, p < .001, so 
degrees of freedom were corrected using Greenhouse-Geisser estimates of sphericity (ε=0.88). A 
main effect of category was found, F(1.8, 274.6) = 1128.40, p < .001, ηp2 = .879, such that 
participants rated neutral stimuli least extremely (in either a positive or negative direction), 
moderate stimuli relatively more extremely than neutral stimuli, and extreme stimuli relatively 
more extremely than moderate stimuli, reflecting normative ratings. 
As expected, however, this analysis yielded a main effect of treatment, F(1,156) = 9.97, p 
= .002, ηp2 = .060, and the predicted interaction of treatment by category, F(1.8, 274.6) = 7.39, p 
= .001, ηp2 = .045 (Figure 2). As with the overall extremity score analyses, participants taking 
acetaminophen were overall less extreme in their evaluations across categories (M = 1.62) 
compared to participants receiving placebo (M = 1.86). Contrast analyses within each category 
revealed that participants taking acetaminophen evaluated extreme stimuli (M = 2.99) 
significantly less extremely (in either a positive or negative direction) than did participants 
receiving placebo (M = 3.47, p < .001). Likewise, participants taking acetaminophen evaluated 
moderate stimuli (M = 1.54) significantly less extremely relative to participants receiving 
placebo (M = 1.78, p = .030). Evaluation extremity toward neutral stimuli did not differ as a 
function of treatment across studies, p = .834.  
Finally, participants’ raw evaluations were submitted to a 2 [Treatment: acetaminophen, 
placebo] x 5 [Normative Rating: extremely unpleasant, moderately unpleasant, neutral, 
moderately pleasant, extremely pleasant] mixed-model ANOVA. Mauchly’s test indicated that 
the assumption of sphericity had been violated, χ2(9) = 227.68, p < .001, so degrees of freedom 
were corrected using Huynh-Feldt estimates of sphericity (ε=0.54). A main effect of category 
was found, F(2.2, 338.1) = 1198.03, p < .001, ηp2 = .885, such that participants rated extremely 
unpleasant pictures more negatively and extremely pleasant pictures more positively in a linear 
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fashion, reflecting normative ratings. There was no main effect of treatment on evaluations, 
F(1,156) = 1.55, p = .215, ηp2 = .010, indicating that treatment did not significantly change 
overall evaluations in any one direction. 
Unsurprisingly, however, as shown in the past two studies, this main effect of category 
was qualified by a significant interaction of treatment by category, F(2.2, 338.1) = 7.51, p < 
.001, ηp2 = .046 (Figure 3). Contrast analyses revealed that participants taking acetaminophen 
rated extremely unpleasant stimuli (M = -3.35) significantly less negatively than participants 
receiving placebo (M = -3.75, p = .009). As predicted, participants taking acetaminophen also 
rated extremely pleasant stimuli (M = +2.59) significantly less positively than participants 
receiving placebo (M = 3.19, p < .001). Likewise, participants taking acetaminophen tended to 
rate moderately pleasant stimuli (M = +1.25) less positively than participants receiving placebo 
(M = +1.55, p = .067), although this difference was only marginally significant. Finally, 
participants taking acetaminophen additionally tended to rate moderately unpleasant stimuli less 
negatively (M = -1.68) and neutral stimuli less positively (M = -0.004) compared to participants 
receiving placebo (Ms = -1.90, +0.12, ps = .161, .102, respectively), although these differences 
were not statistically significant. Thus, the results across studies 1 and 2 illustrate that 
aceatminophen blunted participants’ evaluations toward both unpleasing and pleasing 
experiences, and this effect was most pronounced for stimuli that were more extreme in either a 
negative or positive direction. 
Emotional Arousal 
On emotional arousal, we first submitted participants’ overall emotional arousal to all 
stimuli to an independent-samples t-test, with treatment as the between-participants factor. This 
analysis yielded a significant result, t(156) = 2.76, p = . 006, ηp2 = .047 (Figure 4). Specifically, 
participants taking acetaminophen were overall less emotionally aroused by the stimuli (M = 
4.74) compared to participants receiving placebo (M = 5.29). 
Next, we submitted participants’ emotional arousal to the stimuli as categorized by their 
neutral, moderate, or extreme normative ratings to a 2 [Treatment: acetaminophen, placebo] x 3 
[Normative Rating: neutral, moderate, or extreme] mixed-model ANOVA, with treatment as 
between-participants and normative rating as within-participants factors. Mauchly’s test 
indicated that the assumption of sphericity had been violated, χ2(2) = 68.03, p < .001, so degrees 
of freedom were corrected using Hunyh-Feldt estimates of sphericity (ε=0.75). A main effect of 
category was found, F(1.5, 233.4) = 792.26, p < .001, ηp2 = .835, such that participants were least 
emotionally aroused by neutral stimuli, were relatively more emotionally aroused by moderate 
pleasant and unpleasant stimuli, and were most emotionally aroused by extreme pleasant and 
unpleasant stimuli, reflecting normative ratings. 
As expected, however, this analysis yielded a significant main effect of treatment, 
F(1,156) = 7.38, p = .007, ηp2 = .045, and a significant interaction of treatment by category, 
F(1.5, 233.4) = 4.59, p = .019, ηp2 = .029 (Figure 5). As seen in the prior analyses, participants 
taking acetaminophen were overall less emotionally aroused across categories (M = 4.75) 
compared to participants receiving placebo (M = 5.27). Contrast analyses within each category of 
stimuli revealed that participants taking acetaminophen were significantly less emotionally 
aroused by extreme stimuli (M = 6.88) than were participants receiving placebo (M = 7.77, p = 
.001). Likewise, participants taking acetaminophen were significantly less emotionally aroused 
by moderate stimuli (M = 4.93) relative to participants receiving placebo (M = 5.48, p = .032). 
Participants’ emotional arousal toward neutral stimuli did not differ as a function of treatment 
across the two studies, p = .468. 
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Finally, we submitted participants’ emotional arousal ratings within each of the five 
normative categories to the same 2x5 mixed-model ANOVA as with their evaluations. Mauchly’s 
test indicated that the assumption of sphericity had been violated, χ2(9) = 112.91, p < .001, so 
degrees of freedom were corrected using Huynh-Feldt estimates of sphericity (ε=0.73). A main 
effect of stimulus category was obtained, F(2.9, 441.0) = 454.45, p < .001, ηp2 = .744, such that 
participants expressed higher emotional arousal toward stimuli that were normatively more 
extreme in valence in a quadratic fashion, with the highest arousal toward extremely unpleasant 
and extremely pleasant stimuli, and the lowest arousal toward neutral stimuli. 
As expected based on previous analyses, however, a significant main effect of treatment 
was obtained, F(1,156) = 8.31, p = .004, ηp2 = .051, as was the predicted interaction, F(2.9, 
441.0) = 2.70, p = .047, ηp2 = .017 (Figure 6). As in prior analyses, participants taking 
acetaminophen reported lower levels of arousal toward all stimuli (M = 5.21) than did 
participants taking placebo (M = 5.81). Contrast analyses indicated that participants taking 
acetaminophen were significantly less emotionally aroused by extremely pleasant stimuli (M = 
5.98) than were participants taking placebo (M = 7.07, p < .001). Similarly, participants receiving 
acetaminophen were significantly less emotionally aroused by extremely unpleasant stimuli (M = 
7.78) and moderately unpleasant stimuli (M = 5.90) than were participants assigned the placebo 
condition (Ms = 8.47, 6.49, ps = .025, .048, respectively). Furthermore, participants taking 
acetaminophen marginally significantly less emotionally aroused by moderately pleasant stimuli 
(M = 3.97) than participants taking placebo (M = 4.46, p = .088). Participants did not differ in 
their emotional arousal toward neutral stimuli as a function of treatment across studies, p = .468. 
In all, acetaminophen (versus placebo) attenuated participants’ emotional reactivity more 
potently toward stimuli that were increasingly extreme in valence, regardless of their negative or 
positive content. 
 
Mediation model: Tylenol  Arousal  Extremity, b = -.11,  
99% CI: [-.2349, -.0022] 
99.9% CI: [-.3236, +.0241] 
Mediation model: Tylenol  Extremity  Arousal, b = -.29,  
99% CI: [-.5878, -.0747] 
99.9% CI: [-.7090, -.0070] 
 
(** Figures 1-6 around here **) 
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Figure 1. Effect of treatment on evaluation extremity toward all stimuli. Error bars represent 
95% confidence intervals. 
 
 
 
Figure 4. Effect of treatment on emotional arousal toward all stimuli. Error bars represent 95% 
confidence intervals. 
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Figure 2. Effect of treatment on evaluation extremity toward neutral, moderate, and extreme 
stimuli. Error bars represent 95% confidence intervals. 
 
 
 
Figure 5. Effect of treatment on emotional arousal toward neutral, moderate, and extreme 
stimuli. Error bars represent 95% confidence intervals. 
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Figure 3. Effect of treatment on evaluations toward each category of stimuli. Error bars represent 
95% confidence intervals. 
 
 
 
Figure 6. Effect of treatment on emotional arousal toward each category of stimuli. Error bars 
represent 95% confidence intervals. 
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General Discussion 
In two studies, we demonstrated that acetaminophen desensitizes individuals’ sensitivity 
to evaluations of negative and positive experiences alike. These results replicate and expand on 
past work, illustrating that acetaminophen can blunt the intensity with which individuals 
experience negative events that originate from physical (McQuay et al., 2007), social (DeWall et 
al., 2010), or cognitive sources (DeWall et al., 2014; Randles et al., 2013), even when those 
experiences are merely depicted pictorally. These results also extend our knowledge of the 
effects of acetaminophen on social perception by illustrating that its mechanism of “pain relief” 
might ironically diminish the pleasure with which people enjoy positive experiences as well. 
Critically, this observed effect of acetaminophen was unique to judgments of valence and their 
consequent degree of affective intensity, without affecting other non-evaluative judgments of 
magnitude toward the same stimuli. In other words, acetaminophen seems to relieve pain by 
altering how people perceive any and all emotionally-relevant information, be it negative or 
positive in nature. Rather than being labelled as a pain reliver, acetaminophen might be better 
described as an emotion reliever.  
It seems that using acetaminophen for the treatment of pain has far broader consequences 
than previously thought. Given that evaluations are critical for predicting how people form 
attitudes and behave when navigating their immediate and future environments (Fazio, Eiser, & 
Shook, 2004), a better understanding of the neurochemical influences on processes related to 
attitude formation can inform researchers of how risk-averse and how reward-sensitive 
individuals feel when presented an opportunity to act on their differentially sensitive evaluative 
judgments. Such direct consequences of taking acetaminophen might include attenuated valence 
weighting biases toward both positive and negative information in individuals’ social 
environments (Belsky & Pluess, 2009; Pietri, Shook, & Fazio, 2013; Rocklage & Fazio, 2014), 
reduced responsiveness to persuasion (Petty & Wegener, 1998), and fewer negative and positive 
reactions leading to diminished feelings of ambivalence (Priester & Petty, 1996).  
Some limitations should be noted. Specifically, the abnormal response patterns on 
normative evaluations and emotional arousal ratings in both studies were unexpected. We suspect 
that many (if not all) of these participants were simply not taking the experiment seriously, but 
this remains speculative. Future studies can examine these responses with greater attention, and 
specifically whether these abnormal patterns reflect psychologically meaningful or unmeaningful 
differences between participants. It is also possible, for example, that acetaminophen not only 
attenuates individuals’ mean-level reactions to negative and positive experiences but also affects 
to a lesser extent the degree to which they vary in their reactivity to these experiences. Future 
research on acetaminophen and its effects on cognitive and evaluative processes might better 
disentangle its specific mechanism, such as whether it affects relatively more automatic versus 
controlled processes relevant to evaluation and emotional regulation.  
In sum, the potential implications of attenuated evaluation extremity and emotional 
arousal due to acetaminophen encompass multiple disciplines across psychological and 
biological sciences. There remain several interesting directions for future research on the effects 
of acetaminophen (among other neurochemical modulators), as highlighted above. These 
findings are what we hope to be representative of a larger research movement in social, 
developmental, and cognitive psychology that employs neurochemical measures and 
manipulations to study the complex relationship between our understanding of fine-grained 
neurochemical system regulation with a full appreciation of the depth of human experience. 
[546w] 
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